Measure Up 1

Evaluation of an Active Drug in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)- Measure Up 1

Brief summary

The objective of this study is to assess the efficacy and safety of an active drug for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.

Interventional study

Active, not recruiting
Atopic Dermatitis
912 patients
  • 1
  • 2
  • 3
  • 4
Protocol ID:
Intervention model:
Parallel Assignment
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)


Eligibility criteria

Participant attributes:
Male and Female


From 12 Years to 75 Years.

Inclusion Criteria:

- Body weight of ≥ 40 kg at Baseline Visit for participants between ≥ 12 and < 18 years
of age

- Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years before Baseline
Visit and subject meets Hanifin and Rajka criteria.

- Active moderate to severe AD defined by:

- Eczema Area and Severity Index (EASI) score ≥ 16 at the Screening and Baseline

- Validated Investigator's Global Assessment (vIGA) score ≥ 3 at the Screening and
Baseline Visits;

- ≥ 10% Body surface area (BSA) of AD involvement at the Screening and Baseline

- Baseline weekly average of daily Worst Pruritus NRS ≥ 4.

- Candidate for systemic therapy or have recently required systemic therapy for AD

- Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days
before the Baseline Visit.

- Documented history of inadequate response to topical corticosteroids (TCS) or topical
calcineurin inhibitor (TCI) or documented systemic treatment for AD within 6 months
before Baseline Visit

Exclusion Criteria:

- Prior exposure to any Janus kinase (JAK) inhibitor

- Unable or unwilling to discontinue current atopic dermatitis treatments prior to the

- Requirement of prohibited medications during the study

- Other active skin diseases or skin infections requiring systemic treatment or would
interfere with appropriate assessment of atopic dermatitis lesions

- Female subject who is pregnant, breastfeeding, or considering pregnancy during the

All the cities where the clinical studies are located

Calgary - T2G 1B1
Calgary - T2J 7E1
Surrey - V3R 6A7
Surrey - V3V 0C6
St. John's - A1A 4Y3
Hamilton - L8S 4K1
London - N6H 5L5
Markham - L3P 1X2
Ottawa - K2C 3N2
Waterloo - N2J 1C4
Montreal - H3H 1V4
Montréal - H2X 2V1
Saint-Jerome - J7Z 7E2
Fredericton - E3B 1G9
Winnipeg - R3M 3Z4


British Columbia


New Brunswick

Newfoundland and Labrador

More information about this study